
Aglip12.5 mg
Eskayef Bangladesh Ltd.
Alogliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Alogliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Alogliptin is not a substitute for insulin in patients who require insulin and should not be used to treat diabetic ketoacidosis.
| Indication / Situation | Recommended Dose |
|---|---|
| Type 2 diabetes, normal or mild renal impairment (CrCl ≥60 mL/min) | Alogliptin 25 mg orally once daily |
| Moderate renal impairment (CrCl 30 to <60 mL/min) | Alogliptin 12.5 mg orally once daily |
| Severe renal impairment or end-stage renal disease requiring dialysis | Alogliptin 6.25 mg orally once daily (administer without regard to timing of dialysis) |
Alogliptin may be taken with or without food. It is generally used as monotherapy or in combination with other antidiabetic agents (metformin, a sulfonylurea, pioglitazone, or insulin), with doses of concomitant sulfonylurea or insulin sometimes reduced to lower hypoglycemia risk (see Interactions).
Most patients tolerate Alogliptin well. Reported adverse effects include:
Alogliptin is contraindicated in patients with:
Alogliptin should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis, as it is not effective in these settings.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.